(Press-News.org) New York, NY (November 12, 2025) – A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner.
Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works by using a patient's own T cells, which are genetically engineered in a lab to target and kill cancer cells that have B cell maturation antigen (BCMA) on their surface. The modified T cells are then infused back into the patient as a one-time treatment to fight the cancer.
This study reveals that long-term remission depends on a synergy between the infused CAR T cells and the patient’s own immune system, particularly the preservation of diverse T cells and the absence of suppressive myeloid cells.
“CAR T cell therapy has changed myeloma care, but not everyone maintains a long remission,” said Alessandro Lagana, PhD, Assistant Professor of Oncological Sciences at the Icahn School of Medicine at Mount Sinai and senior author of the study. “We wanted to understand what’s happening in the immune system of patients who stay in remission for more than five years after a single infusion.”
The Mount Sinai team followed 19 patients who received cilta-cel as part of the CARTITUDE-1 clinical trial and used advanced lab tests to study their blood and bone marrow samples before and after treatment.
The study identified several immune features linked to long-term remission. Patients who stayed cancer-free for more than five years showed an early, focused expansion of CAR T cells and a broad, diverse population of healthy helper (CD4) T cells that remained active over time. In contrast, patients who relapsed sooner had higher tumor burden at baseline and an early rise in immunosuppressive myeloid cells that can blunt T cell responses.
“This research shows that long remissions depend not only on the CAR T cells we give, but also on the patient’s own immune system,” Dr. Lagana said. He explained that understanding these immune patterns could help doctors choose the right patients for CAR T cell therapy, watch for early signs of relapse, and develop new treatments that keep the immune system strong and responsive.
The researchers plan to test their findings in larger studies and to create a simple blood test or biomarker panel that could predict which patients are most likely to stay in remission.
The study received funding from Mount Sinai’s Center of Excellence for Multiple Myeloma and included collaborations with Johnson & Johnson, which developed the CAR T cell therapy, and Immunai, which helped with data analysis.
###
About the Icahn School of Medicine at Mount Sinai
The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.
The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows.
Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.
-------------------------------------------------------
* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.
END
As climate change increases the frequency of droughts, UCLA and UC Davis researchers found one overlooked side effect: People report more conflicts with wildlife during drought, when resources are scarce.
For every inch that annual rainfall decreases, scientists found a 2% to 3% increase in reported clashes with a variety of carnivores during drought years, according to a paper published today, Nov. 12, in the journal Science Advances.
The researchers pored through seven years of data from the Wildlife Incident Reporting database, run by the California Department of Fish and Wildlife. The results are likely broadly applicable outside of California, said lead author Kendall Calhoun, ...
Mutations drive evolution, but they can also be risky. New research led by plant biologists at the University of California, Davis, published Nov. 10 in Proceedings of the National Academy of Sciences, reveals how plants control mutation rates in different stem cells to balance adaptability with safety and stability. The findings have implications for breeding some of the world’s most important fruit and vegetable crops, such as potatoes and bananas.
The researchers showed that DNA mutations accumulated up to 4.5 times more frequently in the stem cells that produce a plant’s ...
The Cyvia and Melvyn Wolff Center for Entrepreneurship in the University of Houston’s C.T. Bauer College of Business has once again been named the No. 1 undergraduate entrepreneurship program.
The Wolff Center is the first undergraduate program to secure seven consecutive No. 1 rankings on The Princeton Review’s list, besting its own record of six consecutive wins in the 2025 ranking last November.
Each year, The Princeton Review ranks undergraduate and graduate entrepreneurship programs based on a survey of nearly 300 schools across the U.S., Canada, Mexico and Europe. ...
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) survivors encounter rare, life-threatening drug reactions and years of physical, emotional and social consequences long after leaving the hospital, according to a study published today in JAMA Dermatology.
Investigators from Vanderbilt University Medical Center’s Center for Drug Safety and Immunology (CDSI), in collaboration with the VUMC Qualitative Research Core, conducted one of the largest qualitative studies in the United States exploring SJS/TEN recovery and long-term residual effects from the patients’ ...
EMBARGOED FOR RELEASE UNTIL 4 P.M. ET, WEDNESDAY, NOVEMBER 12, 2025
Highlights:
Your income may be associated with your risk factors for dementia.
Researchers found that having a lower income was associated with a higher prevalence of dementia risk factors like hearing loss, high blood pressure, depression and physical inactivity.
For people living below the poverty level, one in five cases of dementia may be associated with vision loss and social isolation in older people.
After adjusting for income, several risk factors still showed higher prevalence among historically underrepresented groups in clinical research, including diabetes, physical inactivity, obesity and vision ...
In a groundbreaking study, scientists from the Texas A&M College of Veterinary Medicine and Biomedical Sciences (VMBS) have utilized cutting-edge artificial intelligence methods to identify a region of the X chromosome that has maintained the distinctiveness of mammal species for millions of years.
Their findings shed new light on how species maintain their genetic identity, even when hybridization acts to homogenize their gene pools.
“We know that species like big cats; wolves, dogs and coyotes; and even whales and dolphins have interbred ...
The transmission of malaria by the Anopheles cruzii mosquito in the South and Southeast of Brazil was so alarming in the 1940s – with approximately 4,000 cases per 100,000 people – that the disease became known as bromeliad malaria. This is because the Kerteszia subgenus of the mosquito, which transmits the disease in the Atlantic Forest, develops only in bromeliads, plants that accumulate water and maintain conditions favorable for the development of this and other species.
Although ...
RIVERSIDE, Calif. -- Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors including pancreatic cancer. They designed compounds that bind to Pin1 and destabilize its structure, causing its cellular degradation.
This approach not only targets cancer cells directly but also addresses tumor-supporting cells like cancer-associated fibroblasts and macrophages where Pin1 is active, potentially overcoming the treatment resistance posed by the fibrous tumor microenvironment in pancreatic cancer.
The UCR team led ...
Three Tufts faculty have been named to a ranking of the world’s most highly cited researchers. The researchers in the Clarivate 2025 list have a significant impact on the research community as judged by the rate their work is cited by their peers, according to Clarivate, an information and analytics firm focused on research.
The highly cited papers rank in the top 1% by citations for a field or fields and publication year, and only about 1 in 1,000 researchers worldwide qualify.
The Tufts researchers are Chunmei Li, Renata Micha, and Dariush Mozaffarian.
For this year’s analysis, the ...
Huntsman Cancer Institute at the University of Utah (the U) has opened its first specialized angiography-CT suite to enhance treatment options offered in interventional radiology, a field of medicine that uses imaging to conduct minimally invasive procedures. The only one of its kind in the Mountain West, this new technology aims to improve patient outcomes and reduce travel burdens for patients.
“I am thrilled to be able to offer this novel technology in the care of our cancer patients from across ...
